IITRI is proud to share the promising news from multiple sponsors of COVID-19 in vitro and in vivo studies. Links below to press releases and recent publications. Congrats all!
New IITRI Co-Author Publication: Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy (Codagenix, Inc.)
New Partner Publication from In Vitro Data at IITRI: A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry (University of Pittsburgh Medical Center (UPMC))
Research Project Aids in Treatment Going to Clinical Trials: Inhalation Studies of Recombinant Human Angiotensin Converting Enzyme 2 (National Cancer Institute (NCI))
“These studies are being performed to meet a critical and immediate medical need. Although the rollout of COVID-19 vaccines has begun, many millions of people have not been vaccinated and remain at risk of the disease. Development of safe and effective agents to prevent and/or treat COVID-19 has the potential to save thousands of lives.” (IIT Tech News Article about NCI research project)
IITRI continues to support many biotech, academic institions, and small pharma to develop and test efficacy and safety of new COVID-19 preventatives and treatments. Read more about our COVID-19 services here.